Sharemaestro company-news research for Bristol-Myers Squibb Company (BRM), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
GER
Germany
Measured evidence
Company news sentiment
BRM news sentiment
Bristol-Myers Squibb Company
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone66Neutral is 50
Constructive news tone
79/100 evidence confidence
100% direct company focus
14 current stories across 1 publishers
Current company news
Balanced read
Constructive news tone is drawn from 14 fresh independent stories, including 14 company-specific items across 1 publishers.
Latest source headline Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines? finance.yahoo.com · 12 Aug 2026 18:36What supports the read
14 current stories are mapped specifically to BRM.
Cross-story agreement is 83/100, indicating a comparatively coherent tape.
What tempers the read
Only 1 publisher currently contribute to the measured read.
66/100
Weighted toneConstructive news tone
79/100
Evidence confidencesolid confidence
100%/100
Company focus14 direct stories
83/100
Evidence agreement17/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth100
12.91 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness74
recency-weighted evidenceAgreement83
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
News tone and price action are not far from neutral.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment confirms active trendPositive but stretched
News subjects
What is shaping the score
Earnings698 stories · 57%
Deals and strategy644 stories · 29%
Regulatory and legal881 stories · 7%
Analyst action731 stories · 7%
Source mix
Where the evidence comes from
finance.yahoo.com7014 stories · 100%
Recurring subjects
Subjects appearing most often
Earnings9Pharma7Oncology5Biotech4Earnings Per Share3Revenue Growth2Price Target2Manufacturing2Immuno Oncology2Guidance2
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#186Tone
finance.yahoo.comDirect company coverage
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy — is becoming central to top-line resilience. Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving r
Immuno OncologyOncologyPharmaRevenue Growth
- Published
- 12 Aug 2026 18:36
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#249Tone
finance.yahoo.comDirect company coverage
Is Bristol Myers’ US$2.3 Billion Houston Manufacturing Campus Altering The Investment Case For BMY?
Bristol Myers Squibb recently announced it will invest about US$2.30 billion in a new 600,000-square-foot modular, multi-modal manufacturing campus at Generation Park in Houston, Texas, expected to support production of small molecules, biologics, and antibody-drug conjugates while creating nearly 500 skilled jobs and about 2,000 construction and indirect roles through 2030. This facility's flexible, automation-ready design and alignment with the company's broader US$40.00 billion U.S. investment plan highlight how BMS is building manufacturing capacity that can adjust to its evolving late-sta
Balance SheetFuture Cash FlowsManufacturingMergersPatent Expirations
- Published
- 12 Aug 2026 15:11
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#350Tone
finance.yahoo.comDirect company coverage
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 20
EarningsGuidanceObesityOncologyPharmaRevenue Growth
- Published
- 12 Aug 2026 15:03
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#473Tone
finance.yahoo.comDirect company coverage
How AstraZeneca’s $400bn deal unravelled
One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now
- Published
- 12 Aug 2026 04:00
- Catalyst
- Analyst action
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#557Tone
finance.yahoo.comDirect company coverage
1 Profitable Stock with Impressive Fundamentals and 2 We Avoid
1 Profitable Stock with Impressive Fundamentals and 2 We Avoid While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my opportunity". Profits are valuable, but they're not everything. At StockStory, we help you identify the companies that have real staying power. That said, here is one profitable company that generates reliable profits without sacrificing growth and two best left off your watchlist. Two Stocks to Sell: Wolverine Worldwide (WWW) Trailin
EarningsEarnings Per ShareFinancialsFree Cash FlowHealthcareReturn On Equity
- Published
- 12 Aug 2026 02:45
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#670Tone
finance.yahoo.comDirect company coverage
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti
M AOncologyPatent ExpiryPharmaSplit
- Published
- 11 Aug 2026 19:34
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#784Tone
finance.yahoo.comDirect company coverage
Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals
During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and acquisitions now that the Biden era of overzealous antitrust enforcement has been replaced by the Trump era of almost non-existent antitrust enforcement. Most companies don't believe this moment can last, so they're taking advantage of it to make deals. When the summer's over, I believe we're going to come back to see
EarningsEarnings Per ShareEarnings ReportFinancial ResultsFinancialsFourth Quarter
- Published
- 11 Aug 2026 05:43
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#887Tone
finance.yahoo.comDirect company coverage
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Immunocore Holdings plc IMCR has gained 21.2% over the past 12 weeks, putting the durability of that advance in focus. Kimmtrak demand and late-stage pipeline progress give investors concrete operating and clinical milestones to watch. The stock's shorter-term gains have been more modest, while valuation and weak Zacks Style Scores temper the case for simply extrapolating the recent move. IMCR's 3-Month Rally Puts Growth in Focus IMCR shares have climbed more than 20% over the past 12 weeks. That compares with gains of 6.4% over four weeks and 0.6% over one week, making the longer recent advan
BiotechClinical TrialsEarningsPrice Target
- Published
- 10 Aug 2026 16:16
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#983Tone
finance.yahoo.comDirect company coverage
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
Immunocore Holdings plc IMCR offers a clear trade-off between commercial momentum and valuation risk. Kimmtrak continues to expand in metastatic uveal melanoma, while late-stage studies could open larger markets. The counterweight is equally clear. IMCR relies on one marketed product, trades above key industry valuation benchmarks and has seen a sharp deterioration in current-year earnings estimates. IMCR's Kimmtrak Growth Supports the Bull Case Second-quarter 2026 revenues rose 18.3% year over year to $115.9 million, driven by higher Kimmtrak volumes in the United States and international mar
EarningsOncologyPharmaPrice Target
- Published
- 10 Aug 2026 15:41
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1034Tone
finance.yahoo.comDirect company coverage
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Immunocore Holdings plc IMCR posted second-quarter 2026 revenues of $115.9 million, up 18.3% year over year and above the Zacks Consensus Estimate of $114 million. The company's loss of 2 cents per share, however, was wider than the consensus estimate of a loss of 1 cent. Kimmtrak remained the central growth driver, while a temporary U.S. distributor stocking benefit complicates the third-quarter setup. Higher research spending and a sizable cash balance also frame the company's push to broaden its melanoma opportunity. IMCR's Q2 Sales Beat Shows Kimmtrak Strength Kimmtrak generated $74.9 mill
Consensus EstimateEarningsMelanomaPharmaRatings
- Published
- 10 Aug 2026 15:39
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1186Tone
finance.yahoo.comDirect company coverage
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock?
Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major's shares have gained 16.2% over the past three months compared with the industry's growth of 6.8%. The stock has also outperformed both the sector and the S&P 500. BMY Outperforms Industry, Sector & S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research The company reported better-than-expected second-quarter results on July 30, supported by robust demand for Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi and Opdualag. Results were also boosted by strong Eliquis performan
BiotechEarningsGeneric CompetitionGuidanceImmuno Oncology
- Published
- 10 Aug 2026 15:15
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1288Tone
finance.yahoo.comDirect company coverage
Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months
Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of positive regulatory developments that substantially reduced uncertainty surrounding RP1's path to commercialization. FDA Approves REPL's RP1 for Advanced Melanoma Earlier this month, the FDA granted accelerated approval to RP1 (vusolimogene oderparepvec) under the brand name Tudriqev, in combination
BiotechEarningsEarnings Per ShareFda ApprovalOncologyRegulation
- Published
- 10 Aug 2026 14:17
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1359Tone
finance.yahoo.comDirect company coverage
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
New State-of-the-Art Facility Will Create Nearly 500 Skilled Jobs and Accelerate the Delivery of Next-Generation Medicines Investment Furthers BMS' $40 Billion Commitment to American Innovation, Manufacturing and Economic Growth PRINCETON, N.J., August 10, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. The campus, at Generation Park in
BiopharmaceuticalFinancial ResultsInnovationManufacturingPharma
- Published
- 10 Aug 2026 13:01
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1448Tone
finance.yahoo.comDirect company coverage
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the ind
BiotechClinical TrialsEarningsFda ApprovalFourth QuarterPharma
- Published
- 07 Aug 2026 18:22
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.